Professor Mirko Trajkovski leads the Laboratory of Metabolic Diseases at the Faculty of Medicine, University of Geneva. He completed his PhD at the International Max Planck School in Dresden (2005), followed by postdoctoral research at ETH Zurich, before establishing his lab at University College London (2012) and moving to Geneva (2013). His work focuses on adipose tissue plasticity , gut microbiota , and their roles in obesity , diabetes , and insulin resistance . Swiss National Science Foundation Professor (2014) ERC Starting Grant (2014) & Consolidator Grant (2019) Dr Walter Seipp Prize & Carl Gustav Carus Prize (2005) His lab investigates fat browning mechanisms , microbiota-host communication , and multi-tissue metabolic regulation using in vivo , in vitro , and human cohort approaches. Recent publications emphasize microbiome-based therapies , temperature effects on metabolism , and gut-bone-adipose crosstalk . Current advisees include PhD student Silas Kieser, with past members like Jing Xue, Salvatore Fabbiano, and Claire Chevalier contributing to immuno-metabolism and microbial engineering projects.
Panagiota (Nota) Klentrou is a Distinguished Professor and Dean of the Faculty of Applied Health Sciences at Brock University, specializing in Kinesiology. Her research focuses on exercise physiology , bone development , and the health implications of sport training in youth , particularly examining cellular mechanisms linking exercise, diet, and lifelong bone health. Supported by NSERC, CIHR, Osteoporosis Canada, and the International Gymnastics Federation Education: PhD, FCSEP (Fellow of the Canadian Society of Exercise Physiology) Her work spans bone physiology , inflammatory responses to exercise , and sclerostin-mediated tissue cross-talk , with recent studies exploring the impact of obesogenic diets , acute exercise , and nutritional interventions on skeletal growth and adaptation. Key findings include the role of sprint interval training in modulating adipose tissue Wnt signaling and the effects of dairy consumption on bone turnover markers. Scientific Awards & Distinctions Fellow, Canadian Society for Exercise Physiology (CSEP), 2020 Marilyn Rose Graduate Leadership Award, 2017 TVO's Best Lecturer nominee, 2010 Chancellor’s Chair for Research Excellence, Brock University, 2009 Award for Distinguished Research & Creative Activity, Brock University, 2006 Dr. Klentrou actively supervises graduate and undergraduate students in projects related to bone physiology , inflammation , and exercise adaptation , and collaborates with organizations like Osteoporosis Canada and the International Gymnastics Federation.
John F. Brooks II is an Assistant Professor in the Department of Molecular Biology at Princeton University, where he leads the Brooks Lab. His research focuses on the circadian regulation of host-microbe dynamics, particularly how the circadian clock interfaces with the immune system to maintain gut microbiome harmony. Education: Ph.D., Northwestern University Feinberg School of Medicine, Walter S. and Lucienne Driskill Graduate Training Program in Life Sciences B.S., University of Michigan, Microbiology Research Interests: Dr. Brooks investigates how the circadian clock controls the rhythmic secretion of antimicrobial proteins (AMPs) in the small intestine and how persistent infections override these rhythms to sustain AMP production. His work integrates cell and molecular immunology, mouse genetics, and genomics to uncover mechanisms of circadian-immune crosstalk. This research has broad implications for disorders linked to circadian disruption, including obesity, diabetes, and chronic gut inflammation. Recent Publication Trends: His recent publications emphasize the coordination between microbial signals and host circadian rhythms in regulating innate immunity. Key themes include diurnal patterns in immune function, microbiota-driven immune modulation, and the physiological consequences of circadian misalignment in infection and disease. Scientific Awards: Pew Scholar in the Biomedical Sciences (2024) Advising and Grants: Dr. Brooks mentors graduate students and postdoctoral researchers, including Talia Akoh-Arrey and Urbashi Basu. His lab has received significant funding, notably the Pew Biomedical Scholars Award, supporting innovative research at the intersection of immunology, microbiology, and chronobiology. Labs and Teams: The Brooks Lab at Princeton employs interdisciplinary approaches to study host-microbe interactions. The team collaborates with experts in immunology and circadian biology, including Lora Hooper and Joseph Takahashi, to advance understanding of temporal regulation in immunity.
Adam de la Zerda is an Associate Professor at Stanford University's Department of Structural Biology (School of Medicine) and Electrical Engineering (by courtesy). He develops advanced optical molecular imaging technologies combining nanoparticle contrast agents and adaptive OCT systems for cancer and ophthalmic disease research. Technion-Israel Institute of Technology (BSc, 2005) Stanford University (PhD, 2011) UC Berkeley (Postdoctoral Fellowship) Research Themes : Virtual biopsy using machine learning-enhanced OCT Gold nanorod-based molecular contrast agents Speckle noise reduction for cellular resolution Needle beam optical coherence tomography angiography His 15 most recent publications demonstrate technical innovations in: Metasurface optics for extended depth-of-field Spectral deconvolution of multiple contrast agents Speckle modulation for improved diagnostic clarity Noninvasive lymphatic system mapping Scientific Honors : Pew-Stewart Scholar for Cancer Research AFOSR Young Investigator NIH Early Independence Award Forbes 30 Under 30 (x2) Chan Zuckerberg BioHub Investigator His lab team has developed clinical prototypes including OcuBell Inc. 's ophthalmic imaging systems and Visby Medical 's diagnostic platforms. Current research spans from in vivo glycoprotein imaging to de novo biosensor development for real-time disease monitoring in awake animal models.
Prof. Oliver Seitz leads the Bioorganic Synthesis research group at the Department of Chemistry, Faculty of Mathematics and Natural Sciences, Humboldt University of Berlin. His lab focuses on cutting-edge chemical biology approaches for protein/nucleic acid interrogation, with recent work advancing DNA/RNA-programmed assemblies for cellular imaging and therapeutic applications. Research spans chemical protein synthesis, glycoprotein/phosphoprotein engineering, and nucleic acid-templated reactions. Key innovations include Forced Intercalation (FIT) probes for wash-free RNA imaging, loss-of-affinity principles for catalytic efficiency, and peptide-PNA conjugates for targeted cellular delivery. The group actively develops tools for live-cell protein labeling and biomolecular spatial screening. Recent publications (2021-2024) emphasize fluorescence-based detection systems, catalytic templated reactions, and therapeutic peptide synthesis. Trends show increasing sophistication in multi-dye probes, glycan engineering, and RNA-triggered pro-drug activation. Scientific awards include: Max Bergmann Award (2019) Prof. Seitz actively advises doctoral students, with recent graduates Marvin Björn Stutz (2023, magna cum laude ), Dino Gluhacevic von Krüchten (2023, summa cum laude ), and Sophie Schöllkopf (2023, magna cum laude ). Current PhD candidates include Ekaterina Kazakova (glycoprotein synthesis), Alina Herfort (phosphoproteins), and Lina-Marie Beck (peptide-nucleic acid conjugates), with postdocs like Dr. Mandana Oloub (viscosity sensors). The Bioorganic Synthesis lab operates within Berlin's vibrant chemical research ecosystem, utilizing specialized techniques for chemical protein synthesis and nucleic acid detection. Recent team growth reflects ongoing projects in RNA imaging, catalytic templated reactions, and therapeutic conjugate development, supported by open positions for new researchers.
Tyler Johnson, PhD, is an Associate Professor in the Department of Natural Sciences and Mathematics at Dominican University of California's School of Health and Natural Sciences. His expertise lies in Natural Products Chemistry , Bioorganic Chemistry , and Medicinal Chemistry , with a focus on biomedical applications. Johnson's research emphasizes discovering therapeutic lead compounds and molecular probes from marine and terrestrial natural products. His research team investigates chemotypes like mycothiazole , zampanolide , fijianolide , and latrunculin from Indo-Pacific marine sponges. These compounds exhibit potent cytotoxicity (IC50 1~5 nM) against cancer cell lines through mechanisms including microfilament disruption , mitochondrial complex I inhibition , and microtubule stabilization . Current work explores mycothiazole as a molecular probe for mitochondrial aging. Key publications span 2024-2002, covering topics from sponge-derived anticancer agents to inflammation modulation and environmental toxicology. Johnson's laboratory engages in large-scale natural product isolation, spectroscopic validation, and semi-synthetic medicinal chemistry to optimize therapeutic leads. His work integrates undergraduate and graduate students into interdisciplinary biomedical research.
Océane Martin is a Lecturer in Clinical Microbiology at the University of Bordeaux, where she conducts her research at the Institute of Cellular Biochemistry and Genetics, a joint unit of CNRS and the university. Her work bridges clinical microbiology, oncology, and nutritional sciences. Research Interests: Océane Martin specializes in the role of the microbiota in cancer development, particularly focusing on: Links between processed meat consumption, nitrites/nitrates, and colorectal cancer. The role of pathogenic bacteria like Helicobacter pylori and Salmonella in gastric and colorectal cancers. The gut-brain axis in glioblastoma, including how the microbiota influences tumor progression and therapeutic resistance through the GLIOBIOTA project. Intratumoral microbiota in brain tumors and their functional implications. Publication Trends: Her recent publications reflect a strong focus on bacterial genotoxins, DNA damage responses, host immune modulation, and dietary factors in carcinogenesis. Her work integrates molecular microbiology with immunology and cancer biology, often using in vivo models to study host-pathogen dynamics. Scientific Contributions: Member of ANSES working group (2020–2022) on nitrite salts in food. Invited expert at the French National Assembly on nitrite-related health risks. Regular contributor to public science communication via The Conversation and national media. Advising and Grants: While no formal students are listed, her leadership in the GLIOBIOTA project suggests active mentorship and grant-funded research. Her involvement in national expert panels and interdisciplinary projects indicates sustained funding and collaborative research networks. Labs and Teams: She conducts research at the Institute of Cellular Biochemistry and Genetics (University of Bordeaux / CNRS), contributing to teams focused on infection biology, microbiota, and cancer. Her work aligns with translational research initiatives linking diet, microbiology, and oncology.
Kjetil Taskén is a full Professor at the Institute for Clinical Medicine, Faculty of Medicine, University of Oslo , and serves as the Director of the Institute for Cancer Research, Oslo University Hospital . He leads the OUS Center for Precision Medicine in Cancer (SEPREK) since 2021 and has held multiple leadership roles in molecular medicine initiatives, including Director of the Norwegian Centre for Molecular Medicine (NCMM) and co-founder of Bioteknologisenteret. Current affiliations: University of Oslo | Oslo University Hospital Education: Dr.med. (Molecular Cell Biology) | Cand.med. | Research Leadership Course Research interests include immunoregulation in cancer , precision oncology , cellular signal transduction in disease , and drug development targeting immune checkpoints . His work bridges translational immunology and molecular oncology , with a focus on regulatory T cell modulation for cancer therapy. Scientific contributions span high-impact publications on regulatory T cell inhibition , precision medicine implementation , and signal pathway drug targeting . Recent articles highlight collaborations across Europe (PCM4EU, PRIME-ROSE) and Norway (IMPRESS-Norway), with methodological advances in tumor microenvironment modeling and mutation timing analysis . Awards : King Olav V Cancer Research Prize | Anders Jahre Medical Prize | Faculty Medal (UiO) | Norwegian Academy of Science and Letters Leadership : Director of NCMM | Founder of Bioteknologisenteret | Head of multiple national cancer research initiatives Labs and teams include the Cancer Immunology Section at Oslo University Hospital and affiliations with the K. G. Jebsen Center for B-Cell Malignancies , where he co-leads research groups.
Professor Ravi Shukla is a faculty member at RMIT University's School of Science, holding the title of Professor and Deputy Head of Department (Research). He specializes in Nanobiotechnology, with research spanning biomaterials, drug delivery systems, and medical diagnostics. His work integrates biosciences, materials science, and food technology to advance understanding of nanomaterial-biomolecular interactions. Academic History: Professor Shukla has held roles at RMIT since 2011, progressing from Research Fellow to his current professorship. He also serves as an Adjunct Professor at the University of Missouri and Theme Leader for Nanobiotechnology at RMIT’s Center for Advanced Materials and Industrial Chemistry. His teaching focuses on fostering student belonging and innovation in biotechnology education, including coordinating RMIT’s undergraduate Biotechnology program. Research Interests: His lab explores hybrid biomaterial synthesis, nano-enabled proteomics, and non-viral gene therapy using MOFs. Recent work emphasizes applications in diabetes biosensing, CRISPR/Cas9 delivery, and antimicrobial resistance mitigation through nanostrategies. Over 130+ publications and substantial research funding highlight his interdisciplinary impact. Professional Engagement: Editor roles in Frontiers in Bioengineering and Biotechnology , Co-Editor-in-Chief of Current Research in Nutrition and Food Science , and advisor to the Australasian Association of Ayurveda underscore his leadership. He actively mentors students in projects like nano-antimicrobial wound healing and aptamer-based hepatitis A detection. Key Achievements: Pioneered nucleic acid-encapsulated MOFs for cancer therapy and developed paper-based biosensors for rapid diagnostics. His work aligns with UN Sustainable Development Goals 2 (Zero Hunger) and 3 (Good Health).
Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.
Mahima Swamy is a Principal Investigator and Wellcome Trust Sir Henry Dale Fellow at the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU) at the University of Dundee. Her research focuses on understanding immune interactions at the intestinal epithelium, particularly the role of intraepithelial lymphocytes (IEL) in maintaining gut homeostasis and resisting infections. She leads a lab investigating IEL biology, including their regulation by PIM kinases and LRRK2 in inflammatory bowel diseases (IBD) and Crohn’s disease. Dr. Swamy earned her BSc in Biological Sciences from BITS Pilani and completed her PhD at the Max-Planck Institute in Freiburg, Germany. She held postdoctoral fellowships at CRUK London Research Institute and the University of Dundee before establishing her independent group in 2016. Her work combines proteomics, mouse models, and in vitro co-cultures to explore IEL signaling pathways and their dysregulation in diseases. Key research interests include: IEL-mediated protection against pathogens, metabolic adaptations of IEL to the gut environment, and the role of LRRK2 in intestinal immune function. Her lab collaborates with the Alessi lab to study LRRK2 inhibitors for IBD therapy. Education: BSc (BITS Pilani) → PhD (MPIIB, Germany) → Postdocs (CRUK, Dundee) Lab Members: Includes PhD students (Rebecca Pemberton, Srishti, Neema Skariah) and postdocs (Amanpreet Chawla, Purbasha Bhattacharya) Collaborations: Tayside Immunology Group, Society for Mucosal Immunology Scientific achievements include discoveries of PIM kinases in IEL function and LRRK2’s role in gut inflammation. Her group has pioneered tools like phospho-proteomic analyses and epithelial organoid:IEL co-cultures.
Raymond Andersen is a Professor in the Faculty of Science at the University of British Columbia, affiliated with the Department of Earth, Ocean & Atmospheric Sciences and the Department of Chemistry . His research focuses on the isolation and structural elucidation of bioactive natural products from marine and terrestrial organisms, with applications in drug discovery and chemical ecology. He has contributed to breakthroughs in anticancer agents, antiviral compounds, and inhibitors of Mycobacterium tuberculosis. Education: B.Sc. (University of Alberta, 1969), M.Sc. (Berkeley University, 1970), Ph.D. (University of California San Diego, 1975), followed by postdoctoral training at MIT (1975-76). Awards include the Killam Research Prize (1987), Rutherford Medal in Chemistry (1988), and Fellow of the Chemical Institute of Canada. Research interests span marine invertebrate-derived metabolites, phytoplankton toxins, and plant defensive compounds. His lab investigates antitumor agents, HIV latency reversal, and novel pharmacophores for cancer and infectious diseases. Recent work includes antiviral agents targeting SARS-CoV-2 and inhibitors of androgen receptor signaling in prostate cancer. Co-developed clionamine B, an autophagy-stimulating compound effective against latent tuberculosis. Identified sintokamides as androgen receptor antagonists for prostate cancer therapy. Advanced genome-mining techniques for discovering nonribosomal peptides. Overseen numerous graduate students, including notable theses on natural product synthesis, SAR studies, and bioactivity screening. Active in collaborative drug discovery projects, with patents on androgen receptor modulators, SHIP1 activators, and antiviral agents. Labs/Teams: Leads the Andersen Research Group at UBC, focusing on marine natural products and chemical genetics. Collaborates with the Pacific Museum of Earth and Bamfield Marine Sciences Centre for field studies.
Frida Hållenius is an Associate Professor and Senior Lecturer in Molecular Nutrition at the Division of Food and Pharma, Faculty of Engineering (LTH), Lund University. She is a key member of the LTH Profile Area: Food and Bio and leads or actively participates in multiple research projects exploring the role of diet and gut microbiota in human health. Associate Professor in Molecular Nutrition Senior Lecturer, Division of Food and Pharma Faculty of Engineering (LTH), Lund University Principal Investigator, Gut Microbiome Laboratory (GML) Active researcher in 3 ongoing projects, including NeuroFood and ScanOats Her research is centered on host-microbiota interactions, particularly how dietary components, probiotics, and polyphenols influence gut health, inflammation, metabolic diseases, and neuroinflammation. Her work bridges nutrition, microbiology, and neuroscience, with a strong focus on preventive strategies for lifestyle-related diseases such as obesity, diabetes, and Alzheimer’s disease. She employs both animal models (e.g., C57BL/6, Apoe-/- mice) and human-relevant in vitro systems to study dietary interventions. The recent trends in her publications highlight a strong focus on the gut-brain axis, the impact of Nordic berries and legumes on microbiota and metabolic health, and the use of advanced models like 3D intestinal tissue. Her work often involves interdisciplinary collaboration and contributes to multiple UN Sustainable Development Goals, particularly those related to good health and well-being. Scientific Awards: No specific awards mentioned in the provided text. She has supervised several junior researchers and students, including research students and assistants, and is actively involved in grant-funded research projects from FORMAS and private foundations. She leads the Gut Microbiome Laboratory (GML), a collaborative research environment focused on understanding how diet shapes the gut microbiome and influences disease pathways. Her leadership in projects like NeuroFood and those targeting Alzheimer’s disease underscores her commitment to translational nutritional science.
Dr. Rebecca Clark is an Associate Professor in the Department of Biosciences at Durham University. Her research focuses on understanding intestinal function in health and disease using the Drosophila model. She investigates how the intestinal epithelium balances barrier function, nutrient absorption, microbial symbiosis, and cell turnover, particularly during aging and disease states. Key research questions include mechanisms of intestinal barrier failure and the interplay between nutrition and intestinal homeostasis. Her work integrates genetic, microbiological, and physiological approaches to explore aging-related pathologies. Current projects aim to identify molecular pathways linking intestinal health to longevity. Supervised postgraduate students include Ale Acevedo Marcelin, Beñat Yanez, and Fanila Shahzad. Dr. Clark’s lab uses Drosophila as a model system due to its powerful genetic tools and evolutionary relevance. Research has implications for understanding human conditions such as inflammatory bowel disease and age-related metabolic disorders. Recent findings highlight microbiota-independent aging mechanisms and the role of tricellular junctions in stem cell regulation. No scientific awards are explicitly listed in the provided materials. Her research has been published in journals like Cell , Nature Cell Biology , and Proceedings of the National Academy of Sciences .
Dr. Nika Danial is an Associate Professor of Cell Biology at Harvard Medical School and the Department of Cancer Biology at Dana-Farber Cancer Institute. She leads the Danial Lab, investigating metabolic mechanisms that regulate cellular adaptation to stress, with a focus on fuel utilization in health and disease. Dr. Danial holds additional roles as Co-Director of the NCI-funded T32 Training Program in Cancer Chemical Biology and Metabolism. Her research integrates biochemistry, mouse models, and metabolomics to study metabolic contributions to cancer, diabetes, and neurological disorders. Education: PhD from Columbia University (1999), postdoctoral training at Harvard Medical School and Dana-Farber under Dr. Stanley Korsmeyer. Key research areas include mitochondrial dynamics, glucose metabolism pathways, and the interplay between inflammation and metabolic signaling. The lab has pioneered studies on how metabolic flexibility impacts disease progression in pancreatic islets, lymphoma subtypes, and neuronal excitability. Publications highlight discoveries in mitochondrial fatty acid oxidation regulation, urea cycle anti-inflammatory mechanisms, and metabolic signatures in cancer subtypes. Her work has implications for developing therapies targeting metabolic vulnerabilities in diseases like diffuse large B-cell lymphoma and type 1 diabetes. The Danial Lab emphasizes rigorous training for the next generation of scientists through mentorship programs and interdisciplinary collaboration.
